NOVABIO Research Profile

What Is Glycyl-L-histidyl-L-lysine Copper (GHK-Cu)?

GHK-Cu is a copper-containing tripeptide complex identified by the established GHK-Cu abbreviation. This page identifies the material as Glycyl-L-Histidyl-L-Lysine Copper (GHK-Cu), with amino acid count 3; synonyms Copper Tripeptide-1; Copper Peptide GHK-Cu. The GHK-Cu identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Exact-product regulatory reviewLast verified 2026-10-06
Catalogue identityGlycyl-L-Histidyl-L-Lysine Copper (GHK-Cu)
Available specifications50mg, 100mg
Evidence snapshot2 trials · 84 publications
Last verified2026-10-06

What Is Glycyl-L-histidyl-L-lysine Copper (GHK-Cu)?

GHK-Cu is a copper-containing tripeptide complex identified by the established GHK-Cu abbreviation. This page identifies the material as Glycyl-L-Histidyl-L-Lysine Copper (GHK-Cu), with amino acid count 3; synonyms Copper Tripeptide-1; Copper Peptide GHK-Cu. The GHK-Cu identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

2ClinicalTrials.gov query records
84PubMed query records
6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for GHK-Cu is organized around copper-peptide coordination, tripeptide characterization, metal-complex analysis, and analytical peptide workflows. For GHK-Cu, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / StudyPhaseStatusContextLast registry update
NCT07706361Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy AdultsNANot Yet RecruitingGHK and GHK-Cu Blood Levels2026-07-15
NCT07437586Topical GHK-Cu Gel for Acute Skin Wound HealingPhase 2RecruitingAcute Standardized Cutaneous Wounds (Punch-biopsy Wounds)2026-02-27

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective.

BioImpacts : BI · 2025

PMID 39963574
Selected PubMed record

Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.

International journal of molecular sciences · 2018 Jul 7

PMID 29986520
Selected PubMed record

The potential of GHK as an anti-aging peptide.

Aging pathobiology and therapeutics · 2020 Mar 27

PMID 35083444
Selected PubMed record

Glycyl-l-histidyl-l-lysine-Cu(2+) rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway.

Journal of cachexia, sarcopenia and muscle · 2023 Jun

PMID 36905132
Selected PubMed record

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

The American journal of sports medicine · 2026 Jan

PMID 41476424
Selected PubMed record

An injectable hydroxyapatite microsphere filler loaded with GHK-Cu tripeptide for anti-Inflammatory and antioxidant.

Colloids and surfaces. B, Biointerfaces · 2025 Dec

PMID 40716276

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend
Glycyl-L-Histidyl-L-Lysine Copper (GHK-Cu)
Available Specifications
50mg, 100mg
Pack Format
10 Vials
CAS Number
89030-95-5
Molecular Formula
C14H23CuN6O4+
Molecular Weight
402.9 g/mol
Amino Acid Count
3
Sequence
Gly-His-Lys (copper(II) complex)
Synonyms
Copper Tripeptide-1; Copper Peptide GHK-Cu
Physical Form
Lyophilized powder
Salt / Counter-Ion Form
Copper(II) coordination complex of GHK; this is a metal-peptide complex rather than a simple peptide salt.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: PubChem CID 71587328 · Product form must still be matched to the catalogue and batch record.

Research Tools for Glycyl-L-histidyl-L-lysine Copper (GHK-Cu)

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA
Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

Glycyl-L-histidyl-L-lysine Copper (GHK-Cu) Research Summary

Identity

Glycyl-L-Histidyl-L-Lysine Copper (GHK-Cu); specifications: 50mg, 100mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

The research record for GHK-Cu is organized around copper-peptide coordination, tripeptide characterization, metal-complex analysis, and analytical peptide workflows. For GHK-Cu, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Evidence

2 registry records and 84 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Glycyl-L-histidyl-L-lysine Copper (GHK-Cu) is represented here by the catalogue identity Glycyl-L-Histidyl-L-Lysine Copper (GHK-Cu). Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 50mg, 100mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for GHK-Cu is organized around copper-peptide coordination, tripeptide characterization, metal-complex analysis, and analytical peptide workflows. For GHK-Cu, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 2 ClinicalTrials.gov records and 84 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

Glycyl-L-histidyl-L-lysine Copper (GHK-Cu) FAQ

What is Glycyl-L-histidyl-L-lysine Copper (GHK-Cu)?

GHK-Cu is a copper-containing tripeptide complex identified by the established GHK-Cu abbreviation. This page identifies the material as Glycyl-L-Histidyl-L-Lysine Copper (GHK-Cu), with amino acid count 3; synonyms Copper Tripeptide-1; Copper Peptide GHK-Cu. The GHK-Cu identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

What research records are indexed for Glycyl-L-histidyl-L-lysine Copper (GHK-Cu)?

The synchronized query returned 2 ClinicalTrials.gov records and 84 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is Glycyl-L-histidyl-L-lysine Copper (GHK-Cu) FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources
ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved
2026-10-06T12:08:49Z
Inclusion
Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations
Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by
NOVABIO Research
Reviewed date
2026-10-06
Editorial methodology
How NOVABIO builds Research Profiles
Corrections contact
Contact NOVABIO with the page URL and source record.